Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities Post published:December 20, 2021 Post category:Press Release
MYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias Post published:December 17, 2021 Post category:Press Release
MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD Post published:December 17, 2021 Post category:Press Release
COMPASS Selected for Addition to NASDAQ Biotechnology Index Post published:December 17, 2021 Post category:Press Release
Psyched Wellness Announces Path to Market for AME-1-derived Products in the USA Post published:December 16, 2021 Post category:Press Release
COMPASS Pathways announces changes in Executive Team Post published:December 16, 2021 Post category:Press Release
MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022 Post published:December 16, 2021 Post category:Press Release
Entheon Biomedical Announces EEG Patent Application & Provides Research Update Post published:December 16, 2021 Post category:Press Release
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics Post published:December 16, 2021 Post category:Press Release
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights Post published:December 15, 2021 Post category:Press Release